Aim: BRAF is one of the serine threonin kinases that activates mitogen activated protein kinase (MAPK) signal pathway.The aim of this study is to evaluatethe relationship between extrathyroidal extension (ETE) and BRAFV600E mutation in the subjects with papillary thyroid cancer.
Materials and methods: Clinical and laboratory data of 455 patients, who had been followed-up in our clinic between the years 2010 and 2015 for PTC, were evaluated. The relationship between extrathyroidal extension and BRAFV600E mutation was examined in the subjects enrolled in the study.
Results: Among 455 patients, 382 (83.9%) were female and 73 (16.1%) were males. The mean age of the participants was 49±11.8 years. While 368 (80.9%) of the patients had no extrathyroidal extension, 87 (19.1%) of the patients had extrathyroidal extension. 362 (79.6%) of the patients were BRAFV600E mutation (−) and 93 (20.4%) patients were BRAFV600E mutation (+). 320 patients were negative for both BRAFV600E mutation and extrathyroidal extension. The prevalence of PTC larger than 1 cm was significantly more common among BRAFV600E mutation and ETE (+) cases (P:0.004). The prevalence of capsular, lymphovascular and perineural invasion, lymph node metastasis and ultrasonographically detected pathologic lymphadenopathy was significantly higher among BRAFV600E mutation (+) and ETE(+) subjects (P:0.004, P<0.05, P<0.05, P:0.05, P:0.01).
Conclusion: In this study, BRAFV600E mutation and ETE positivity were found to be poor prognostic parameters in the patients with PTC. However, the evaluation of long term follow-up data is required to more clearly understand prognostic effect and especially to determine the effect of this situation on mortality.
20 - 23 May 2017
European Society of Endocrinology